x

Posted 10 October, 2023

Poseida Therapeutics, Inc. appointed Kristin Yarema, Ph.D. as new CEO

Nasdaq:PSTX appointed new Chief Executive Officer Kristin Yarema, Ph.D. in a 8-K filed on 10 October, 2023.


  On October 5, 2023, the Board of Directors (the "Board") of Poseida Therapeutics, Inc. (the "Company") approved a leadership transition appointing Kristin Yarema, Ph.D., as President and Chief Executive Officer of the Company.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Poseida Therapeutics, Inc.
Health Care/Life Sciences • Pharmaceuticals
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.
Market Cap
$352M
View Company Details
Poseida Therapeutics, Inc. by TradingView
Relevant filing section
Item 5.02 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


On October 5, 2023, the Board of Directors (the "Board") of Poseida Therapeutics, Inc. (the "Company") approved a leadership transition appointing Kristin Yarema, Ph.D., as President and Chief Executive Officer of the Company. Dr. Yarema currently serves as President, Cell Therapy of the Company. The Board also appointed Mark Gergen, the Company's current President and Chief Executive Officer, as Executive Chairman of the Board. The leadership transition is anticipated to be effective as of January 1, 2024 (the "Effective Date"). 

Prior to the Effective Date, the Company will enter into amended employment agreements and related benefits and compensatory arrangements with each of Dr. Yarema and Mr. Gergen. The current employment agreement with each of Dr. Yarema and Mr. Gergen are filed as exhibits to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, filed with the Securities and Exchange Commission (the "SEC") on May 9, 2023 and the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 9, 2023, respectively. Biographical information about each of Dr. Yarema and Mr. Gergen is described in the Company's definitive proxy statement on Schedule 14A, filed with the SEC on April 26, 2023. 

There is no arrangement or understanding between Dr. Yarema and any other person pursuant to which she was selected as an officer of the Company, and there are no family relationships between Dr. Yarema and any of the Company's directors or executive officers. There are no transactions to which the Company is a party and in which Dr. Yarema has a direct or indirect material interest that would be required to be disclosed under Item 404(a) of Regulation S-K.